Nanoparticle-drug conjugates treating bacterial infections

Jelínková, Pavlína; Mazumdar, Aninda; Sur, Vishma Pratap; Kočiová, Silvia; Dolezelikova, Kristyna; Jiménez, Ana María Jiménez; Koudelková, Zuzana; Mishra, Pawan Kumar; Šmerková, Kristýna; Heger, Zbyněk; Vaculovičová, Markéta; Moulick, Amitava; Adam, Vojtěch

doi:10.1016/j.jconrel.2019.06.013

Cited by 70 publications

(31 citation statements)

References 227 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The deposited metal nanoparticles can penetrate the bacterial membrane, allowing better intercalation of the conjugated MDPs within the inner membrane, thus making the MDP-AuNP conjugates more active than the nonconjugated MDP itself. Taking advantage of individual components, several bioconjugates composed of metal nanoparticles and membrane-disruptive peptides/polymers have been developed, and show promising therapeutic efficacy against bacterial infection 177 , 178 , 179 .…”

Section: Multi-drug Combination Therapymentioning

confidence: 99%

Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era

Lin

Chi

Yan

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Membrane-disruptive peptides/peptidomimetics (MDPs) are antimicrobials or anticarcinogens that present a general killing mechanism through the physical disruption of cell membranes, in contrast to conventional chemotherapeutic drugs, which act on precise targets such as DNA or specific enzymes. Owing to their rapid action, broad-spectrum activity, and mechanisms of action that potentially hinder the development of resistance, MDPs have been increasingly considered as future therapeutics in the drug-resistant era. Recently, growing experimental evidence has demonstrated that MDPs can also be utilized as adjuvants to enhance the therapeutic effects of other agents. In this review, we evaluate the literature around the broad-spectrum antimicrobial properties and anticancer activity of MDPs, and summarize the current development and mechanisms of MDPs alone or in combination with other agents. Notably, this review highlights recent advances in the design of various MDP-based drug delivery systems that can improve the therapeutic effect of MDPs, minimize side effects, and promote the co-delivery of multiple chemotherapeutics, for more efficient antimicrobial and anticancer therapy.

show abstract

Section: Multi-drug Combination Therapymentioning

confidence: 99%

Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era

Lin

Chi

Yan

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…10 However, the effectiveness of some antibiotics as antimicrobials have limitations that include poor penetrability, which prevents the drug from reaching the minimum inhibitory concentration (MIC) level in bone tissue. 11,12 In addition, high doses of antibiotics administered systemically can induce serious side-effects such as ototoxicity and nephrotoxicity. Given these limitations, there is a clear need for the development of delivery carriers for controlled VCM release to improve its antimicrobial activity and reduce side-effects.…”

Section: Introductionmentioning

confidence: 99%

<p>Injectable Chitosan-Based Thermosensitive Hydrogel/Nanoparticle-Loaded System for Local Delivery of Vancomycin in the Treatment of Osteomyelitis</p>

Jin¹,

Zhang²,

Shen³

et al. 2020

IJN

View full text Add to dashboard Cite

Purpose: Osteomyelitis, particularly chronic osteomyelitis, remains a major challenge for orthopedic surgeons. The traditional treatment for osteomyelitis, which involves antibiotics and debridement, does not provide a complete solution for infection and bone repair. Antibiotics such as vancomycin (VCM) are commonly used to treat osteomyelitis in clinical settings. VCM use is limited by a lack of effective delivery methods that provide sustained, high doses to entirely fill irregular bone tissue to treat infections. Methods: We engineered a chitosan (CS)-based thermosensitive hydrogel to produce a VCM-nanoparticle (NPs)/Gel local drug delivery system. The VCM-NPs were formed with quaternary ammonium chitosan and carboxylated chitosan nanoparticles (VCM-NPs) by positive and negative charge adsorption to enhance the encapsulation efficiency and drug loading of VCM, with the aim of simultaneously preventing infection and repairing broken bones. This hydrogel was evaluated in a rabbit osteomyelitis model. Results: The VCM-NPs had high encapsulation efficiency and drug loading, with values of 60.1±2.1% and 24.1±0.84%, respectively. When embedded in CS-Gel, the VCM-NPs maintained their particle size and morphology, and the injectability and thermosensitivity of the hydrogel, which were evaluated by injectability test and rheological measurement, were retained. The VCM-NPs/Gel exhibited sustained release of VCM over 26 days. In vitro tests revealed that the VCM-NPs/Gel promoted osteoblast proliferation and activity against Staphylococcus aureus. In vivo, VCM-NPs/Gel (with 10 mg vancomycin per rabbit) was used to treat rabbits with osteomyelitis. The VCM-NPs/Gel showed excellent anti-infection properties and accelerating bone repair under osteomyelitis conditions. Conclusion: The reported multifunctional NPs hydrogel system for local antibiotic delivery (VCM-NPs/Gel) showed bone regeneration promotion and anti-infection properties, demonstrating significant potential as a scaffold for effective treatment of osteomyelitis.

show abstract

“…Despite the availability of several broad-spectrum antimicrobial components, antimicrobial resistance is a worldwide health emergency, and it is an enormous challenge for the effective therapy and remedy of many common infections [3,4]. Resistance to antimicrobial components can be defined as the ability of a disease-causing microorganism to resist the therapeutic effects of drugs [5]. As a result, standard treatments become useless, and contaminations persist and may spread to others.…”

Section: Introductionmentioning

confidence: 99%

Metal and Metal Oxide Nanoparticle as a Novel Antibiotic Carrier for the Direct Delivery of Antibiotics

Kotrange

Najda

Bains

et al. 2021

IJMS

View full text Add to dashboard Cite

In addition to the benefits, increasing the constant need for antibiotics has resulted in the development of antibiotic bacterial resistance over time. Antibiotic tolerance mainly evolves in these bacteria through efflux pumps and biofilms. Leading to its modern and profitable uses, emerging nanotechnology is a significant field of research that is considered as the most important scientific breakthrough in recent years. Metal nanoparticles as nanocarriers are currently attracting a lot of interest from scientists, because of their wide range of applications and higher compatibility with bioactive components. As a consequence of their ability to inhibit the growth of bacteria, nanoparticles have been shown to have significant antibacterial, antifungal, antiviral, and antiparasitic efficacy in the battle against antibiotic resistance in microorganisms. As a result, this study covers bacterial tolerance to antibiotics, the antibacterial properties of various metal nanoparticles, their mechanisms, and the use of various metal and metal oxide nanoparticles as novel antibiotic carriers for direct antibiotic delivery.

show abstract

Nanoparticle-drug conjugates treating bacterial infections

Cited by 70 publications

References 227 publications

Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era

Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era

<p>Injectable Chitosan-Based Thermosensitive Hydrogel/Nanoparticle-Loaded System for Local Delivery of Vancomycin in the Treatment of Osteomyelitis</p>

Metal and Metal Oxide Nanoparticle as a Novel Antibiotic Carrier for the Direct Delivery of Antibiotics

Contact Info

Product

Resources

About